CDC123 Antibody

Introduction to CDC123 Antibody

CDC123 antibody is a research tool used to detect the CDC123 protein (Cell Division Cycle 123 Homolog), a conserved eukaryotic protein critical for translation initiation and cell cycle regulation. It binds to specific epitopes of CDC123, enabling its detection in immunological assays such as Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and flow cytometry (FC). CDC123 functions as an ATP-dependent chaperone for the eIF2 complex, facilitating its assembly and enabling translational initiation during cellular growth and stress responses .

Antibody Types and Applications

CDC123 antibodies are categorized by host species, isotype, and conjugation status:

• Monoclonal Antibodies:

  • Mouse-derived: ABIN563857 (IgG2a) and sc-390989 (IgG2b κ) for WB, ELISA, and IHC .

  • Rabbit-derived: Abcam’s ab129101 (recombinant monoclonal) for WB and intracellular flow cytometry .

• Polyclonal Antibodies:

  • Rabbit: Proteintech’s 10595-2-AP (ELISA) and Abcam’s ab238560 (IHC) .

• Applications:

  • Western Blotting: Detects CDC123 in lysates (e.g., HeLa, 293T) .

  • Immunohistochemistry: Identifies CDC123 in paraffin-embedded tissues .

  • Flow Cytometry: Intracellular staining in permeabilized cells .

Research Findings on CDC123 Function

CDC123 is essential for:

1. eIF2 Complex Assembly: Binds the γ-subunit of eIF2, promoting its interaction with α/β subunits to enable translation initiation .

2. Cell Cycle Regulation: Prevents G1/S phase arrest by destabilizing checkpoint proteins like Chfr .

3. Cancer Biology:

   • Breast Cancer: Overexpression correlates with USP9X-mediated deubiquitination, promoting tumor proliferation .

   • Translation Control: Knockdown reduces polysome formation and increases stress-response genes like GCN4 .

Clinical Relevance and Therapeutic Potential

While CDC123 antibodies are primarily research tools, their findings inform therapeutic strategies:

• Breast Cancer: Targeting the USP9X/CDC123 axis may suppress tumor growth .

• Diagnostic Biomarkers: CDC123 expression levels could serve as markers for luminal breast cancers .

• Limitations: Current antibodies lack therapeutic conjugation; their clinical utility remains focused on preclinical studies .